Zanubrutinib
This oral BTK (Bruton's tyrosine kinase) inhibitor is used to treat certain types of blood cancers including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia, and mantle cell lymphoma. It works by blocking the BTK enzyme that B-cell cancers depend on for their growth and survival signals. Compared to earlier BTK inhibitors, it is designed to be more selective in order to reduce off-target side effects.
분자량
471.5000 g/mol
LogP
3.50
TPSA
102.00 Ų
리핀스키 5의 법칙
통과
치료 영역
작용 기전
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
2D 구조
Cite this structure
Embed this structure
SMILES
C=CC(=O)N1CCC([C@@H]2CCNc3c(C(N)=O)c(-c4ccc(Oc5ccccc5)cc4)nn32)CC1
InChI
InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18,22,29H,1,12-17H2,(H2,28,34)/t22-/m0/s1
Molecular Formula
C27H29N5O3
HBD / HBA
2 / 5
회전 가능 결합
6
무거운 원자
35
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
This oral BTK (Bruton's tyrosine kinase) inhibitor is used to treat certain types of blood cancers including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), Waldenström's macroglobulinemia, and mantle cell lymphoma. It works by blocking the BTK enzyme that B-cell cancers depend on for their growth and survival signals. Compared to earlier BTK inhibitors, it is designed to be more selective in order to reduce off-target side effects.
Irreversibly inhibits Bruton's tyrosine kinase (BTK), a key enzyme in the B-cell receptor signaling pathway that drives the survival and proliferation of malignant B cells.
Yes, Zanubrutinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3936761. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 135565884. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="zanubrutinib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/zanubrutinib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/zanubrutinib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/zanubrutinib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="zanubrutinib"></drugfyi-drug>